Esophageal Diseases  >>  IMF-001  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMF-001 / ImmunoFrontier
NCT01003808: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

Completed
1
25
Japan
IMF-001, CHP-NY-ESO-1
ImmunoFrontier, Inc.
Esophageal Cancer
03/12
12/12

Download Options